Kyung Hae Jung - Concepedia

Author

Kyung Hae Jung

Also Known As

Dae Yong Kim, Hee Chul Park, JUNG, KYUNG HAE, Jae-Ho Lee, Joo Hyuk Sohn, K H Jung, K Jung, K. H. Jung, K. Jung, K.-H. Jung

449

Publications

15.7K

Citations

H-Index

116

Concepts

All Affiliations

University of Ulsan Asan Medical Center Ulsan College National Cancer Center Seoul National University Hospital

About

Kyung Hae Jung is an author at University of Ulsan specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	38	85	8.6K
2	Health Sciences	19	26	2.2K
3	Nursing	6	6	421
4	Engineering	2	2	58
5	Arts	1	1	146

Kyung Hae Jung

170

Publications

13.9K

Citations

H-Index

Page 1

	Year	Citations
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial Elizabeth A. Mittendorf, Hong Zhang, Carlos H. Barrios, The Lancet Breast OncologyOncologyBreast CancerPharmacotherapyCancer Treatment	2020	1K
Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): short-term outcomes of an open-label randomised controlled trial Sung‐Bum Kang, Ji Won Park, Seung‐Yong Jeong, The Lancet Oncology Low Rectal CancerSurgical OncologyGastrointestinal OncologyMedicineShort-term Outcomes	2010	1K
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial Debu Tripathy, Seock‐Ah Im, Marco Colleoni, The Lancet Oncology Advanced Breast CancerBreast OncologyOncologyEndocrine OncologyMedicine	2018	973
Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial Seung‐Yong Jeong, Ji Won Park, Byung Ho Nam, The Lancet Oncology Low-rectal CancerSurgical OncologyNeoadjuvant ChemoradiotherapyGastrointestinal OncologyMedicine	2014	878
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial Funda Meric‐Bernstam, Vicky Makker, Ana Oaknin, Journal of Clinical Oncology	2023	767
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial Sara A. Hurvitz, Miguel Martín, W. Fraser Symmans, The Lancet Oncology	2017	503
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer Charles E. Geyer, Judy E. Garber, Richard D. Gelber, Annals of Oncology Breast OncologyOverall SurvivalMedicinePathologyGermline Pathogenic Variants	2022	404
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study Éric Pujade-Lauraine, Keiichi Fujiwara, Jonathan A. Ledermann, The Lancet Oncology Chemotherapy Versus ChemotherapyOncologyPlatinum-refractory Ovarian CancerMedicineMetronomic Therapy	2021	374
Lateral Lymph Node Metastasis Is a Major Cause of Locoregional Recurrence in Rectal Cancer Treated with Preoperative Chemoradiotherapy and Curative Resection Tae Hyun Kim, Seung‐Yong Jeong, Dong Hyun Choi, Annals of Surgical Oncology Surgical OncologyColorectal SurgeryCancer RecurrenceRectal Cancer TreatedCurative Resection	2007	320
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors Kyung Hae Jung, Patricia LoRusso, Howard A. Burris, Clinical Cancer Research	2019	281

Page 1